Security key
25253X207
DiaMedica Therapeutics Inc. - Voting Common Shares, no par value (DMAC)
CUSIP: 25253X207
Q2 2024 13F Holders as of 30 Jun 2024
- Security type / class
- Equity / Voting Common Shares, no par value
- Total 13F shares
- 5,062,392
- Total 13F value
- $14,934,296
- Share change
- +462,603
- Put/Call ratio
- 77%
- SEC-reported price per share
- $2.95
- Number of holders
- 32
- Value change
- +$1,369,212
- Number of buys
- 10
- Number of sells
- 13
- Shares outstanding
- 52,272,727
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2024
Institutions
32
Top holders
10
DMAC full security history
Ownership snapshot
Full 13F holder table
DiaMedica Therapeutics Inc. SEC filings
DiaMedica Therapeutics Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of DMAC - DiaMedica Therapeutics Inc. - Voting Common Shares, no par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
VANGUARD GROUP INC
Disclosed value leader
VANGUARD GROUP INC
Comparable rows
15/15
Latest evidence
31 Mar 2024
13F
Lead comparable stake: 1.9%
Showing 1-6 of 15 holder rows.
Quick read
VANGUARD GROUP INC leads the comparable SEC ownership view at 1.9%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens VANGUARD GROUP INC's linked filing trail.
Comparable ownership
Top 5
VANGUARD GROUP INC
1.9%
Leon G. Cooperman
1.7%
FIRST MANHATTAN CO. LLC.
1.6%
PARAGON ASSOCIATES & PARAGON ASSO...
0.96%
GEODE CAPITAL MANAGEMENT, LLC
0.46%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| VANGUARD GROUP INC |
13F
Company
|
1.9%
|
$2,807,456
1,013,522 shares
|
— | 31 Mar 2024 |
| Leon G. Cooperman |
13F
Individual
|
1.7%
|
$2,447,636
883,623 shares
|
— | 31 Mar 2024 |
| FIRST MANHATTAN CO. LLC. |
13F
Company
|
1.6%
|
$2,354,605
850,038 shares
|
— | 31 Mar 2024 |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE |
13F
Company
|
0.96%
|
$1,385,000
500,000 shares
|
— | 31 Mar 2024 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
0.46%
|
$662,841
239,235 shares
|
— | 31 Mar 2024 |
| Bleichroeder LP |
13F
Company
|
0.43%
|
$615,818
222,317 shares
|
— | 31 Mar 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
32
Shares
5,062,392
Rows available
32
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2024 vs Q1 2024 Across Filers
Q1 2024 holders
31
Q2 2024 holders
32
Holder diff
1
| Investor | Q1 2024 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q1 2024 value | Q2 2024 value | Value change | Value Chg % |
|---|